RxDoctor Payments Data

Nicholas Jovanovich

Internal Medicine · Burgettstown, PANPI 1679884290

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 63 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$258
  • Inari Medical, Inc.$196
  • Stryker$170
  • Shockwave Medical, Inc$168
  • AbbVie$146
  • GSK$123
  • plus $631 from 13 others

What the payments were for

  • Food & beverage$1,693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$85,093
Medicare patients
347
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$31,047
JardianceEmpagliflozin16$15,147
OzempicSemaglutide11$14,315
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,742
XareltoRivaroxaban20$11,569
Breo ElliptaFluticasone/Vilanterol18$10,878
Victoza 3-PakLiraglutide11$8,817
Janumet XrSitagliptin Phos/Metformin Hcl12$6,467
SymbicortBudesonide/Formoterol Fumarate13$3,107
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,088
Celecoxib11$1,125
Potassium Chloride55$941
Albuterol Sulfate HfaAlbuterol Sulfate43$897
Levothyroxine Sodium119$871
Losartan Potassium112$810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$123$23,62038 claims
Boehringer IngelheimJardiance$34$15,14716 claims
Novo NordiskOzempic$100$14,31511 claims
AbbVieSynthroid$146$65114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Burgettstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →